Pfizer's neuropsychiatry candidate PF-04958242 was acquired by Biogen for $75 million upfront in a deal that could give Pfizer $515 million in milestones, plus royalties. Biogen plans to begin a Phase IIb study of the candidate for the treatment of cognitive impairment associated with schizophrenia later this year.
Pfizer grants Biogen rights to neuropsychiatry candidate
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.